MICM
ADCT icon

Matthews International Capital Management’s ADC Therapeutics ADCT Stock Holding History

Matthews International Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-607,800
Closed -$14.8M – 50
2021
Q1 		$14.8M Buy
607,800
+368,300
+154% +$10.7M 0.62% 31
2020
Q4 		$7.67M Hold
239,500
– – 0.41% 27
2020
Q3 		$7.9M Hold
239,500
– – 0.53% 24
2020
Q2 		$11.2M Buy
+239,500
New +$9.09M 0.87% 21

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Matthews International Capital Management's ADCT Position: Q2 2021 in Review

Matthews International Capital Management sold out of ADC Therapeutics (ADCT) in Q2 2021, closing a stake of 607,800 shares — an estimated $14.8M sold.

Matthews International Capital Management first reported a position in ADCT in Q2 2020 and held it in 4 quarters. The position peaked at $14.8M in Q1 2021. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2021.

  • Matthews International Capital Management reported no remaining ADC Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Matthews International Capital Management sold 607,800 ADC Therapeutics shares in Q2 2021, an estimated $14.8M.
  • Matthews International Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 4 quarters.
  • Matthews International Capital Management's ADC Therapeutics position peaked at $14.8M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2021.

Based on Matthews International Capital Management's 13F filing for Q2 2021, filed 10 Aug 2021.